Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01976611|
Recruitment Status : Completed
First Posted : November 6, 2013
Last Update Posted : April 8, 2015
|Condition or disease||Intervention/treatment|
|Migraine Disorders Headache||Biological: botulinum toxin Type A|
|Study Type :||Observational|
|Actual Enrollment :||402 participants|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||February 2015|
|Actual Study Completion Date :||February 2015|
Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
Biological: botulinum toxin Type A
Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
- Number of Participants with Adverse Events and Adverse Drug Reactions [ Time Frame: 4 Years ]
- Headache Impact Test-6 (HIT-6) Score Using a 5-Point Scale [ Time Frame: 4 Years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01976611
|Korea, Republic of|
|Seoul, Korea, Republic of|
|Study Director:||Medical Director||Allergan|